# KECHENG INTELLIGENT HEALTH

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kecheng-intelligent-health

- Industry: Pharmaceuticals
- Headquarters: Hefei, China
- Website: www.kchealth.com
- Latest round: Seed (Nov 5, 2023)
- Investors on record: 2

## About

Founded in 2021 and based in Hefei, China, KECHENG INTELLIGENT HEALTH is a cell therapy company that focuses on the research, application and promotion of metabolic remodeling immune cell therapy technology.  Wei Xiong, the company’s chairman and chief scientist, is the deputy dean of the School of Life Sciences at the University of Science and Technology of China and the deputy dean of the Artificial Intelligence Research Institute of the Hefei Comprehensive National Science Center. In 2017, its R&D center was settled in Hefei. In 2022, it established a subsidiary, Glacier Medicine. In November 2023, it closed strategic investment.

KECHENG INTELLIGENT HEALTH's business categories can be divided into three categories, namely, research and development of cell-based drugs, research and development of small molecule drugs, and immune research for special populations. Relying on scientific research platforms such as molecular biochemical research platform and GMP cell preparation platform. It provides cell drug products, such as antitumor drugs, anti-aging drugs, and immunity-enhancing drugs. The company also provides treatment solutions, metabolomics detection and analysis, cell analysis and other services.

## Funding rounds

- Seed, Nov 5, 2023 — Hefei State-Owned Assets Holding, Shanghai Chengsheng

## Investors

- Hefei State-Owned Assets Holding (https://capitalatlas.ai/funds/hefei-state-owned-assets-holding) — Seed
- Shanghai Chengsheng — Seed